AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023 AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 6, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023
(Reuters) - AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023. (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie in deal with Samsung Bioepis to delay Humira biosimilar U.S. launch
(Reuters) - AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023. (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Samsung Bioepis
Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates Samsung Bioepis Acknowledges Validity of AbbVie's Intellectual Property for... Biopharmaceuticals, Litigation, Licensing AbbVie, Samsung Bioepis, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2018 Category: Pharmaceuticals Source Type: news

AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023
(Reuters) - AbbVie Inc on Thursday said it signed a deal with Biogen Inc and its joint venture partner Samsung Bioepis that would fend off U.S. competition of their rival version to blockbuster drug Humira until 2023. (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Adalimumab's Benefits Persist for Spine Disease
(MedPage Today) -- Improvements continued for clinical, functional, and MRI effects (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 28, 2018 Category: Primary Care Source Type: news

AbbVie's lung cancer drug data disappoints; shares slump
(Reuters) - AbbVie Inc's experimental lung cancer drug data was not effective enough to seek a faster approval, in a setback to the company's efforts to build its cancer drug pipeline and cut dependence on its blockbuster Humira. (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Mark Stenhouse to join Exact Sciences as President, Cologuard
After leading HUMIRA sales and marketing to create a blockbuster drug, Abbott Laboratories/AbbVie executive to join Cologuard team MADISON, Wis., March 20, 2018 -- (Healthcare Sales & Marketing Network) -- Exact Sciences Corp. (Nasdaq: EXAS), the compa... Diagnostics, Oncology, Personnel Exact Sciences, Cologuard, colorectal cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2018 Category: Pharmaceuticals Source Type: news

Drug Spend Down in 2017, but Costs Still Up for Specialty Drugs Drug Spend Down in 2017, but Costs Still Up for Specialty Drugs
As in 2016, Humira was among most expensive drugs, but spending on hepatitis C therapies dropped precipitously.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 6, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Drug Costs Slowing Down, but Still High for Specialty Drugs Drug Costs Slowing Down, but Still High for Specialty Drugs
As in 2016, Humira was among most expensive drugs, but spending on hepatitis C therapies dropped precipitously.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 6, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Adalimumab dose escalation for UC treatment costly in Germany
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2018 Category: Drugs & Pharmacology Source Type: news

Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), submitted under the 351 (k) pathway, for proposed biosimilar adalimumab to the reference medicine, Humira®*. (Source: World Pharma News)
Source: World Pharma News - January 16, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Biological Therapies and Improvements in QoL in Psoriasis Biological Therapies and Improvements in QoL in Psoriasis
This study compared the effectiveness of adalimumab, etanercept and ustekinumab on improvements in HRQoL in patients with psoriasis. What factors are associated with these improvements?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Novartis advances head-to-head superiority trials of Cosentyx ® versus Humira®* and proposed biosimilar adalimumab**
Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS). SURPASS is the first head-to-head clinical trial in AS investigating superiority of Cosentyx in slowing spinal bone damage versus proposed biosimilar adalimumab**. SURPASS is currently recruiting patients, with the 'first patient first visit' already achieved in November 2017. (Source: World Pharma News)
Source: World Pharma News - January 9, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Morning Break: Pfizer Kills AD/PD Pipeline; Trump Affirms His Mental Health; Humira Pricing Strategy
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 8, 2018 Category: Primary Care Source Type: news